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Abstract
Aims: Node-positive bladder cancer (NPBC) carries a poor prognosis and has traditionally been treated palliatively. However, surgical series suggest that a subset
of NPBC patients can achieve long-term control after cystectomy and lymph node dissection. There is little published data regarding the use of radiotherapy to
treat NPBC patients. This is in part due to concerns regarding the toxicity of whole-pelvis radiotherapy using conventional techniques. We hypothesised that,
using intensity-modulated radiotherapy (IMRT), the pelvic nodes and bladder could be treated within a radical treatment volume with acceptable toxicity
proﬁles.
Materials and methods: The Intensity-modulated Pelvic Node and Bladder Radiotherapy (IMPART) trial was a phase II single-centre prospective study designed
to assess the feasibility of delivering IMRT to treat the bladder and pelvic nodes in patients with node-positive or high-risk node-negative bladder cancer
(NNBC). The primary end point was meeting predetermined dose constraints. Secondary end points included acute and late toxicity, pelvic relapse-free survival
and overall survival.
Results: In total, 38 patients were recruited and treated between June 2009 and November 2012; 22/38 (58%) had NPBC; 31/38 (81.6%) received neoadjuvant
chemotherapy; 18/38 (47%) received concurrent chemotherapy; 37/38 (97%) patients had radiotherapy planned as per protocol. Grade 3 gastrointestinal and
genitourinary acute toxicity rates were 5.4 and 20.6%, respectively. At 1 year, the grade 3 late toxicity rate was 5%; 1-, 2- and 5-year pelvic relapse-free survival
rates were 55, 37 and 26%, respectively. The median overall survival was 1.9 years (95% conﬁdence interval 1.1e3.8) with 1-, 2- and 5-year overall survival rates
of 68, 50 and 34%, respectively.
Conclusion: Delivering IMRT to the bladder and pelvic nodes in NPBC and high-risk NNBC is feasible, with low toxicity and low pelvic nodal recurrence rates.
Long-term control seems to be achievable in a subset of patients. However, relapse patterns suggest that strategies targeting both local recurrence and the
development of distant metastases are required to improve patient outcomes.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Regional lymph node involvement in bladder cancer is
associated with a poor prognosis. Five-year disease-speciﬁc
survival rates of 31.2% are reported compared with 66.7% in
patients without nodal involvement [1]. The prognosis is so
poor that in most centres, patients with node-positive
bladder cancer (NPBC) have conventionally beenis is an open access article under the CC BY license (http://creativecommons.
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been treated with palliative intent. However, surgical series
have shown that long-term control is achievable in a subset
of patients after cystectomy and lymph node dissection
[2e6] and, when combined with neoadjuvant chemo-
therapy, 5-year cancer-speciﬁc survival rates of up to 63.5%
have been reported in those showing a complete patho-
logical response after chemotherapy [7].
Although surgery has generally been the most common
management of muscle-invasive bladder cancer (MIBC),
bladder preservation strategies with chemoradiation have
become an increasingly accepted alternative. The standard
UK practice is to treat the whole bladder alone to a dose of
64 Gy in 32 fractions or equivalent using three-dimensional
conformal radiotherapy. The pelvis is not routinely treated
due to concerns regarding additional toxicity. Furthermore,
there is little evidence that routine pelvic radiotherapy in
MIBC [8,9] confers any beneﬁt, despite evidence from sur-
gical series showing signiﬁcant rates of micro-metastases
[10,11].
This leaves a signiﬁcant gap in treatment options for
NPBC patients who are not suitable for surgery due to either
comorbidities or personal choice. It could also be suggested
that in patients with NPBC where the prognosis is poor, a
less invasive approach with chemoradiation might be a
more attractive alternative to surgery.
Advances in radiotherapy techniques have allowed more
conformal approaches to be used, suggesting that nodal
treatment could be delivered with acceptable toxicity. The
Intensity-modulated Pelvic Node and Bladder Radiotherapy
(IMPART) trial was designed to assess the feasibility of
delivering intensity-modulated radiotherapy (IMRT) to the
bladder and pelvic nodes, and to assess the clinical out-
comes of patients treated.Materials and Methods
Study Design
In this single-centre phase II study, patients with NPBC or
high-risk node-negative bladder cancer (NNBC) received
IMRT to the bladder and pelvic nodes.13/38 (34.2%) patients
were recruited retrospectively, having completed identical
treatment to that offered within the trial before the study
opened. To minimise potential bias, the retrospective group
consisted of consecutively treated patients, with none
excluded. The study and inclusion of the retrospective
subset were approved by our institutional research com-
mittee and the local research ethics committee.
The primary end point was to assess the feasibility of
meeting predetermined dose constraints. Secondary end
points included assessment of acute toxicity, late toxicity at
1 year after treatment, pelvic relapse-free survival, distant
relapse-free survival, overall survival and bladder cancer-
speciﬁc survival.
Pelvic relapse-free survival was deﬁned as the rate of
survival free of recurrent disease (superﬁcial and/or inva-
sive) in the pelvic nodes or bladder.Please cite this article as: Tan MP et al., The Intensity-Modulated Pelvic No
Prospective Study, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.0Eligibility
Eligible patients were aged 18 years or over with histo-
pathologically proven MIBC and either (i) radiological or
pathological evidence of pelvic nodal metastases or (ii) a
high risk of nodal involvement, i.e. radiological or patho-
logical T3b/T4 disease, or disease with high-risk pathology,
e.g. small cell histology. Patients with pelvic relapse after
radical cystectomy were also eligible.
Patients were required to have had a previous maximal
transurethral resection of bladder tumour. Neoadjuvant
chemotherapy was permitted.
Exclusion criteria included unsuitability for radical
radiotherapy treatment, previous pelvic radiotherapy, in-
ﬂammatory bowel disease or small bowel disease, bilateral
hip replacements, other malignancy (except basal cell car-
cinoma, fully treated in situ cervical carcinoma or incidental
prostate carcinoma) in the past 2 years that might affect
treatment assessment.
All prospectively recruited patients provided written
informed consent. For the retrospective cohort, written
consent was obtained from those who were alive.
Radiotherapy Planning
Patients underwent a radiotherapy planning scan in the
supine position with an empty bladder, Combiﬁx immobi-
lisation and arms positioned across the chest. Slices (2.5
mm) were acquired from the cranial edge of the L3 vertebra
to 1 cm below obturator foramina on a large-bore computed
tomography scanner (Philips, Cleveland, OH, USA). Images
were exported to a planning system (Pinnacle, Philips
Medical, Madison, WI, USA) for target volume outlining.
Radiotherapy Volumes
Four clinical target volumes (CTVs) were outlined:
CTV_whole bladder, CTV_pelvic lymph nodes, CTV_tumour bed and
CTV_involved lymph nodes. Diagnostic imaging was used to assist
outlining. Involved lymph nodes were determined by radiol-
ogist review of initial pre-treatment imaging and included all
pathologically enlarged lymph nodes as per computed to-
mography size criteria [12]. Details of radiotherapy planning
guidelines used are provided in the Supplementary Material.
Anisotropic margins were applied to CTV1 as per previ-
ous work [13]. Our institution standard of 0.5 cm was
applied to the lymph node volumes. A 1 cm uniformmargin
was applied to the tumour bed (CTV3) to ensure coverage
and to take into account possible tethering of the bladder
wall at the site of disease. Table 1 summarises the volumes
deﬁned and expansion margins. Figure 1 illustrates the
volumes created. The organs at risk included the rectum,
other bowel and femoral heads. Table 2 summarises the
predetermined dose constraints set.
Radiotherapy Planning
All subjects were individually inverse-planned using ﬁve
co-planar IMRT beamswith gantry angles of 30, 95,180, 265de and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre
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Table 1
Clinical target volume (CTV) to planning target volume (PTV) margin expansions
CTV1/ PTV1
(whole bladder)
CTV2/ PTV2 (pelvic
lymph nodes)
CTV3/ PTV3 (bladder
tumour bed)
CTV4/ PTV4 (involved
pelvic lymph nodes)
Anterior 1.5 cm 0.5 cm 1.0 cm 0.5 cm
Posterior 1.0 cm 0.5 cm 1.0 cm 0.5 cm
Lateral 0.5 cm 0.5 cm 1.0 cm 0.5 cm
Superior 1.5 cm 0.5 cm 1.0 cm 0.5 cm
Inferior 0.5 cm 0.5 cm 1.0 cm 0.5 cm
M.P. Tan et al. / Clinical Oncology xxx (xxxx) xxx 3and 330. The PTV_whole bladder (excluding PTV_tumour bed)
and PTV_pelvic lymph nodes (excluding PTV_involved lymph nodes)
were prescribed to 52 Gy in 32 fractions, PTV_tumour bed was
prescribed to 64 Gy in 32 fractions and PTV_involved lymph
nodes was prescribed to 60 Gy in 32 fractions. The plan ob-
jectives were for the PTV D99 (i.e. the dose received by 99%
of the PTV), D95 and D50 to be 90, 95 and 100% of the
prescribed dose, respectively.
Where plans failed to meet PTV objectives and/or
optimal organ at risk constraints, the target volumes and
dose distributions were reviewed to produce a clinically
acceptable option. Doses to the whole bladder and tumour
bed were never compromised. Where optimal bowel con-
straints were still notmet, 50% additional volume at the V45
and V50 levels were accepted, providing the V55, V60 and
V65 constraints were not exceeded. If this was still not
achievable, patients were treated to a nodal dose (PTV2) of
48 Gy in 32 fractions.Radiotherapy Delivery
Treatment was delivered daily with cone-beam
computed tomography imaging acquired using a no action
level ofﬂine protocol. Cone-beam computed tomography
images were registered to the computed tomography scan
using bony anatomy and a systematic correction carried out
after the ﬁrst three fractions. Weekly images were reviewed
with a tolerance of 3 mm. Concomitant chemotherapy wasFig 1. Examples of clinical target volumes (CTVs). (a) A coronal
computed tomography slice illustrating CTV_whole bladder in brown,
CTV_pelvic lymph nodes in green, CTV_tumour bed in red and CTV_involved
lymph node in blue. (b) A sagittal computed tomography slice showing
CTV_whole bladder and CTV_pelvic lymph nodes.
Please cite this article as: Tan MP et al., The Intensity-Modulated Pelvic No
Prospective Study, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.0recommended after publication of the BC2001 results [8].
Patients were reviewed weekly during treatment.
Toxicity and Response Assessment
Patients were reviewed weekly during treatment and
acute toxicities recorded using CTCAE v3.0. After radio-
therapy, patients were reviewed at 4, 8 and 12 weeks. Late
toxicity was graded using Radiation Therapy Oncology
Group criteria from week 12. Patients underwent a rigid
cystoscopy at week 12. Patients were then clinically
reviewed every 6 months up to 3 years after radiotherapy,
then annually to 5 years. A chest X-ray was carried out at 6,
18, 30, 36, 48 and 60 months. Computed tomography of the
chest/abdomen/pelvis was carried out at 12 and 24 months.
Flexible cystoscopy was carried out at 6, 12, 18, 24 months,
and then annually to 5 years.
Statistics
The sample size was based on the hypothesis that the
true rate of meeting dose constraints would be in the region
of 70%, and for the feasibility end point we intended to show
that >50% of patients would meet all dose constraints. Us-
ing a Simon two-stage design with a one-sided test at sig-
niﬁcance level 0.05, initial recruitment was set at 23
patients, with a further 14 to be recruited if at least 13/23
met the constraints. The end point would be considered to
have been met if at least 24/37 met the dose constraints.Table 2
Predetermined dose constraints
Organ at risk Dose Maximum volume (% or cm3)
Rectum 30 Gy 80%
50 Gy 60%
60 Gy 50%
65 Gy 30%
70 Gy 15%
75 Gy 5%
Femoral heads 50 Gy 50%
Other bowel V45 139 cm3 optimal (209 cm3 mandatory)
V50 122 cm3 optimal (183 cm3 mandatory)
V55 105 cm3
V60 84 cm3
V65 26 cm3
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M.P. Tan et al. / Clinical Oncology xxx (xxxx) xxx4Toxicity data were analysed in terms of prevalence and
overall frequencies. Survival and recurrence-free estimates
were calculated using KaplaneMeier analysis on an inten-
tion to treat basis. The follow-up time was calculated from
the start date of radiotherapy to the date of death (event) or
the date last known to be alive (censored).
An exploratory analysis was carried out to compare acute
toxicity proﬁles in patients receiving radiotherapy alone
versus chemoradiation, with signiﬁcance assessed using a
Fisher’s exact test. A further exploratory analysis using
KaplaneMeier methods was carried out to look at pelvic
relapse-free and overall survival in patients with NPBC
versus NNBC. The Cox proportional hazard model was used
to calculate hazard ratios with a 95% conﬁdence interval.
Data were analysed using STATA 13.1 for Windows.Results
Between June 2009 and November 2012, 38 patients
were recruited. Patient characteristics are shown in Table 3.
Of the 16/38 (42.1%) patients with NNBC, 11/16 (68.8%) had
T3/4 disease, 4/16 (25.0%) had neuroendocrine differentia-
tion and 1/16 (6.3%) had bulky multifocal disease.
Primary End Point
The radiotherapy plans of 29/38 (76.3%) patients
met all predetermined dose constraints. The remaining
patients failed to meet the ‘other bowel’ dose constraint.Table 3
Patient characteristics
Gender n (%) Female
Male
Age (years) Median
Range
Clinical T stage n (%) T2
T3
T4
Prior cystec
Pathological T stage n (%) pT1
pT2
pT3a/b
pT4
Prior cystec
Not known
Clinical N stage n (%) N0
N1
N2
N3
Histology* n (%) Transitional
Small cell
Squamous c
Not known
Neoadjuvant chemotherapy n (%) Yes
No
Concurrent chemotherapy n (%) Yes
No
* All were high grade.
Please cite this article as: Tan MP et al., The Intensity-Modulated Pelvic No
Prospective Study, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.0A clinically acceptable option was achievable in 5/9
(55.6%) patients without dose reduction; 3/9 (33.3%)
patients required the prescribed dose to PTV2 to be
reduced to 48 Gy in 32 fractions. In one case, the dose
constraints were not achievable even at a reduced dose
prescription.
Overall, 97% (37/38) of patients had radiotherapy plan-
ned as per the study protocol. A total of 35/38 (92.1%) pa-
tients completed radiotherapy as planned.Secondary End Points
Acute Toxicity
One patient died before starting radiotherapy and so was
excluded from the toxicity analysis. As three patients had
had a previous cystectomy, urinary toxicity data were
collected from 34 patients. The results are summarised in
Table 4.
Diarrhoea and urinary frequency/urgency were the most
commonly reported adverse events, affecting 26/37 (70.3%)
and 28/34 (82.4%) patients, respectively. Grade 1/2 gastro-
intestinal and genitourinary adverse events were reported
by 30/37 (81.1%) and 24/34 (70.6%) patients, respectively.
The grade 3 gastrointestinal toxicity rate was 5.4% and the
grade 3 genitourinary toxicity rate was 20.6%. There were
no grade 4 gastrointestinal or genitourinary adverse events.
An exploratory comparison of the maximum toxicity re-
ported by patients receiving radiotherapy alone or chemo-
radiation is shown in the Supplementary Material.7 (18.4)
31 (81.6)
70.7
47e88
11 (28.9)
18 (47.4)
6 (15.8)
tomy 3 (7.9)
2 (5.3)
30 (78.9)
0 (0)
2 (5.3)
tomy 3 (7.9)
1 (2.6)
16 (42.1)
9 (23.7)
9 (23.7)
4 (10.5)
cell 33 (86.8)
3 (7.9)
ell 1 (2.6)
1 (2.6)
31 (81.6)
7 (18.4)
18 (47.4)
20 (52.6)
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Table 4
Acute toxicity
Acute toxicity (CTCAE v3) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Data unavailable*
Gastrointestinal Diarrhoea 10 (27.0%) 17 (46.0%) 8 (21.6%) 1 (2.7%) 0 (0.0%) 1 (2.7%)
Proctitis 25 (67.6%) 5 (13.5%) 6 (16.2%) 0 (0.0%) 0 (0.0%) 1 (2.7%)
Abdominal pain 18 (48.6%) 17 (45.9%) 1 (2.7%) 0 (0.0%) 0 (0.0%) 1 (2.7%)
Nausea 25 (68.0%) 10 (27.0%) 1 (2.7%) 0 (0.0%) 0 (0.0%) 1 (2.7%)
Vomiting 33 (89.2%) 3 (8.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.7%)
Anorexia 21 (56.8%) 7 (18.9%) 7 (18.9%) 1 (2.7%) 0 (0.0%) 1 (2.7%)
Gastrointestinal overall 4 (11.0%) 14 (28.6%) 16 (43.2%) 2 (5.4%) 0 (0.0%) 1 (2.7%)
Genitourinary Urinary frequency/urgency 3 (8.8%) 13 (38.2%) 11 (32.4%) 6 (17.6%) 0 (0.0%) 1 (2.9%)
Cystitis 7 (20.6%) 12 (32.4%) 14 (41.2%) 0 (0.0%) 0 (0.0%) 1 (2.9%)
Urinary incontinence 22 (64.7%) 7 (20.6%) 3 (8.8%) 1 (2.9%) 0 (0.0%) 1 (2.9%)
Retention/hesitancy 20 (58.8%) 11 (32.4%) 1 (2.9%) 1 (2.9%) 0 (0.0%) 1 (2.9%)
Bladder spasm 26 (76.5%) 6 (17.6%) 1 (2.9%) 0 (0.0%) 0 (0.0%) 1 (2.9%)
Genitourinary overall 2 (5.8%) 8 (23.5%) 16 (47.1%) 7 (20.6%) 0 (0.0%) 1 (2.9%)
Other Fatigue 6 (16.2%) 18 (48.6%) 11 (29.7%) 0 (0.0%) 1 (2.7%) 1 (2.7%)
Haemoglobin 4 (10.8%) 23 (62.2%) 9 (24.3%) 0 (0.0%) 0 (0.0%) 1 (2.7%)
* One patient had a 6-week treatment break due to a fractured hip and resumed a hypofractionated schedule off-study. Toxicity data were
therefore not collected.
M.P. Tan et al. / Clinical Oncology xxx (xxxx) xxx 5Late Toxicity
Late toxicity data were collected at a minimum of one
time point from 30/38 (78.9%) patients.
Data were unavailable for 8/38 (21.1%) patients. Of those
withmissing data, 4/8 (50%) died before 12weeks, 2/8 (25%)
relapsed with metastatic disease before 12 weeks and
subsequently died,1/8 (12.5%) withdrew from the study and
1/8 (12.5%) was treated off-protocol.
At 1 year, the grade 3 late toxicity rate was 5%, with one
patient reporting grade 3 cystitis and haematuria. At 2
years, there was no reported grade 3 or 4 toxicity.
Overview of Relapse Patterns
At a median follow-up of 5.2 years, 27/38 (71.1%) patients
had disease recurrence. Atﬁrst relapse,15/38 (39.5%) patientsDistant metastases
Bladder 
recurrence: ≥pT2
Bladder
recurrence: 
Nodal 
recurrence
Fig 2. Proportional Venn diagram illustrating disease patterns at ﬁrs
Please cite this article as: Tan MP et al., The Intensity-Modulated Pelvic No
Prospective Study, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.0had locoregional disease only, 5/38 (13.2%) had both locore-
gional and distant recurrence and 7/38 (18.4%) presented
with distant metastases only; 9/38 (23.7%) patients showed
no evidence of disease recurrence and 2/38 (5.2%) patients
died before/during radiotherapy from unrelated causes.
Four of 15 (26.7%) patients with initial locoregional only
relapse subsequently went on to develop distant metasta-
ses. Disease patterns at ﬁrst relapse are summarised in
Figure 2. Figure 3 shows the KaplaneMeier survival curves.
Pelvic Relapse
Twenty of 38 (52.6%) patients had locoregional disease at
ﬁrst relapse, of whom a quarter had concurrent distant
metastases.
Of the 35 patients with an intact bladder at treatment,11/
35 (31.4%) developed muscle-invasive bladder recurrence 
< pT2
N0
N1
N2
N3
Died from MIBC
Died of other cause 
Cause of death Unknown
Legend
Symbol denotes nodal 
status at diagnosis and shading 
denotes status/cause 
of death
Alive
t relapse and survival status at a median follow-up of 5.2 years.
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Fig 3. KaplaneMeier curves showing: (a) overall survival and bladder cancer-speciﬁc survival, (b) overall survival according to nodal status, (c)
pelvic relapse-free survival, (d) pelvic relapse-free survival according to nodal status, (e) distant recurrence-free survival and (f) distant
recurrence-free survival according to nodal status.
M.P. Tan et al. / Clinical Oncology xxx (xxxx) xxx6(4/11 with concurrent metastases, including one with
additional nodal relapse) and 7/35 (20.0%) developed su-
perﬁcial disease; two of whom subsequently developed
muscle-invasive disease 11 and 12 months later. Two of 38
(5.2%) patients developed isolated pelvic nodal relapse. Ten
of 11 (90.9%) invasive bladder relapses occurred at the same
site as the original disease.
One-, 2- and 5-year locoregional relapse-free survival
rates were 55, 37 and 26%, respectively.
An exploratory analysis comparing locoregional control
in NPBC and NNBC patients did not show a signiﬁcant dif-
ference (P ¼ 0.37).Please cite this article as: Tan MP et al., The Intensity-Modulated Pelvic No
Prospective Study, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.0Salvage cystectomy was carried out in ﬁve patients at a
median of 259 days after radiotherapy (range 146e689).
Three of ﬁve (80%) patients had pT3 disease,1/5 (20%) had
pT1b and Carcinoma in situ (CIS) disease and 1/5 (20%) had a
complete pathological response after re-challenge with
carboplatin and etoposide. The bladder preservation rate for
the cohort overall was 85.7% (30/35).
Distant Relapse
Twelve of 38 (31.6%) patients ﬁrst relapsed with distant
metastatic disease, ﬁve of whom (41.7%) had concurrent
locoregional recurrence.de and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre
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quently went on to develop distant metastatic disease at 1.4
and 4 years after recurrence. A further two patients with
muscle-invasive bladder only disease at ﬁrst relapse went
on to develop distant metastatic disease 10.5 and 9 months
later. Therefore, a total of 16/38 (42.1%) patients developed
distant metastases after radiotherapy, 11 of whom had
NPBC; representing 50% of the 22 NPBC patients.
One-, 2- and 5-year distant metastasis-free survival rates
were 66, 45% and 31%, respectively.
An exploratory analysis comparing distant metastasis-
free survival between NNBC and NPBC patients showed
no signiﬁcant difference (P ¼ 0.93).
Overall Survival
The median overall survival was 1.9 years (95% conﬁ-
dence interval 1.1e3.8) with 1-, 2- and 5-year overall sur-
vival rates of 68, 50 and 34%, respectively.
An exploratory analysis comparing overall survival in
NNBC and NPBC patients showed no signiﬁcant difference
(P ¼ 0.62).
Bladder Cancer-speciﬁc Survival
The median bladder cancer-speciﬁc survival was 2.2
years (95% conﬁdence interval 1.5e not reached) with 1-, 2-
and 5-year bladder cancer-speciﬁc survival rates of 78, 57
and 44%, respectively.Discussion
IMPART has shown that delivering IMRT to the pelvic
nodes and bladder is feasible in terms of meeting pre-
determined dose constraints. This supports the recent work
of Sondergaard et al. [14], who reported statistically signif-
icant normal tissue sparing in a cohort of 16 NNBC patients
when IMRT was used to treat the bladder and the pelvic
lymph nodes compared with a conformal sequential boost
technique. Furthermore, a subset of our cohort achieved
long-term disease control and overall toxicity levels seem to
be in line with those reported in other studies where the
bladder and the pelvic lymph nodes were treated [9,14].
The acute and late gastrointestinal toxicity rates are of
particular interest given the large radiation ﬁelds required
to encompass the pelvic nodes and the proximity of bowel
to the bladder and pelvic nodal volumes. Although 70% of
our patients reported diarrhoea at some point, most cases
were limited to grade 1/2 in severity and only one patient
reported grade 3 diarrhoea. Our grade 1/2 gastrointestinal
toxicity rate of 81.1% compares favourably with an IMRT
study [14] where equivalent rates of 75% were reported in a
cohort of NNBC patients receiving 48 Gy in 30 fractions to
the pelvic nodes without concomitant chemotherapy. Our
slightly higher toxicity rates are probably due to the dif-
ference in nodal dose delivered and the fact that 50% of our
cohort also received concomitant chemotherapy, which is
associated with increased bowel toxicity [8].Please cite this article as: Tan MP et al., The Intensity-Modulated Pelvic No
Prospective Study, Clinical Oncology, https://doi.org/10.1016/j.clon.2019.0It is interesting to note that although concerns
regarding the inclusion of the pelvic nodes in the radia-
tion ﬁeld have been primarily based on concerns
regarding bowel toxicity, we found that the grade 3/4
urinary toxicity rates were higher than those reported for
gastrointestinal adverse effects. We suggest, therefore,
that our results are encouraging with regards to bowel
toxicity and support previous work suggesting that
existing bowel constraints are too conservative in the
setting of bladder cancer [15].
A review of the relapse patterns seen in this cohort is
important in deﬁning how to improve treatment. The rate
of pelvic nodal relapse was low and actually little different
to the rate seen after bladder-only radiotherapy (<6%) [8],
suggesting that the nodal doses used in this study are
sufﬁcient to attain control in most patients. Local relapse in
these high-risk patients, both invasive and non-invasive,
however, was more common. Only half of patients
received concurrent chemotherapy, which would now be
considered as best practice as it was shown to signiﬁcantly
reduce locoregional recurrence in the BC2001 trial. Of
those not receiving concurrent chemotherapy, 12 patients
were treated before publication of BC2001 changed our
routine practice and six patients had comorbidities pre-
cluding concurrent treatment. These data, however, do
lend support to investigating strategies to improve local
control. This might include additional concomitant thera-
pies or dose-escalation strategies to the tumour bed. We
have recently reported results of dose escalating the
tumour dose in standard-risk patients to 70 Gy/32 frac-
tions [16] and are currently studying this approach in NPBC
patients.
The high incidence of distant metastatic relapse, despite
most patients receiving neoadjuvant chemotherapy, after
radical treatment demonstrated in this cohort emphasises
the poor prognosis and systemic nature of the disease and
highlights the ongoing need for more efﬁcacious systemic
treatment options. Exploration of additional treatment ap-
proaches, such as immune checkpoint (PD-1, PDL-1) in-
hibitors, might be of interest.
Despite this, recurrence-free survival and overall survival
seem to plateau after 3 years, with a subset of patients
showing long-term disease control. Our 5-year overall sur-
vival rate of 34% is comparable with the 5-year cancer-
speciﬁc survival of 29.2% in 149 NPBC patients undergoing
neoadjuvant chemotherapy and surgery [2].
Our exploratory analysis showed no signiﬁcant differ-
ence in outcome between NPBC and NNBC. However, over
two-thirds of those with NNBC had T3/4 disease and 19%
had small cell histology. Both of these features are associ-
ated with a poor prognosis and so the lack of difference
between the subgroups is perhaps not so surprising.
The limitations of this study include the fact that this was
a small and heterogeneous cohort, which included NPBC,
NNBC, post-cystectomy and retrospectively recruited pa-
tients, thus limiting the power of any clinical outcome
analysis. However, the primary aim of this study was to
assess the feasibility of delivering IMRT to the bladder and
pelvic nodes, and this was met.de and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre
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IMRT to the bladder and pelvic nodes in MIBC is feasible
in terms of meeting dose constraints and shows an
acceptable adverse effect proﬁle. Although many centres
have traditionally adopted a palliative approach to NPBC,
our results support existing surgical data demonstrating
that a subset of NPBC patients can achieve long-term con-
trol after radical treatment and IMPART suggests that che-
moradiation could offer an alternative to surgery for such
patients. However, further work is required to fully evaluate
the role of nodal irradiation in MIBC. Identifying ‘treatment
responders’ will be key and will probably rely on both
clinicopathological features and translational biomarkers.
There remains, however, a high risk of developing distant
disease in MIBC and so optimisation of local treatment
alone is insufﬁcient. Strategies to target distant metastases
and, if possible, prevent the development of metastases
remain crucial in the management of this poor-prognosis
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